Gilead and partners reported deep and durable responses with anito‑cel in a pivotal multiple myeloma trial, with a high overall response rate and a substantial complete remission fraction in the presented cohort. The press release cited 96% tumor response and 74% complete remissions among trial participants in the analysis. Kite and Gilead executives used ASH presentations to argue anito‑cel is poised for wide use, positioning it as a next‑generation competitor to existing myeloma CAR‑T therapies. Trial authors emphasized durability and manageable safety in the dataset. Companies are preparing commercial and manufacturing scale‑up while regulators assess pivotal data; success would extend CAR‑T into larger myeloma patient populations and shape future standards of care.